Cargando…
NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon response
Novel adjuvants are needed to increase the efficacy of vaccine formulations and immune therapies for cancer and chronic infections. In particular, adjuvants that promote a strong type I IFN response are required, since this cytokine is crucial for the development of efficient anti-tumoral and anti-v...
Autores principales: | Oberson, Anne, Spagnuolo, Lorenzo, Puddinu, Viola, Barchet, Winfried, Rittner, Karola, Bourquin, Carole |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814164/ https://www.ncbi.nlm.nih.gov/pubmed/29464024 http://dx.doi.org/10.18632/oncotarget.23725 |
Ejemplares similares
-
HMGB1 promotes CXCL12‐dependent egress of murine B cells from Peyer's patches in homeostasis
por: Spagnuolo, Lorenzo, et al.
Publicado: (2021) -
hnRNPH2 as an Inhibitor of Chicken MDA5-Mediated Type I Interferon Response: Analysis Using Chicken MDA5–Host Interactome
por: Lin, Xian, et al.
Publicado: (2020) -
Filovirus VP24 Proteins Differentially Regulate RIG-I and MDA5-Dependent Type I and III Interferon Promoter Activation
por: He, Felix B., et al.
Publicado: (2022) -
Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients
por: Qian, Jinjing, et al.
Publicado: (2023) -
Anti-MDA5 Antibody Linking COVID-19, Type I Interferon, and Autoimmunity: A Case Report and Systematic Literature Review
por: Tonutti, Antonio, et al.
Publicado: (2022)